What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in overall survival (Duration of (high certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  HR 0.94 [0.84, 1.05]
  4 studies · 3848 participants
  High

Intervention not reported

The intervention showed no clear difference in progression‐free survival (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  HR 0.94 [0.86, 1.03]
  5 studies · 3861 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival: 1‐year survival rate  (low certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.02 [0.96, 1.08]
  7 studies · 4420 participants
  Low

Intervention not reported

The intervention showed no clear difference in overall survival: 2‐year survival rate (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.02 [0.93, 1.12]
  7 studies · 4420 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival: 3‐year survival rate (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 0.99 [0.9, 1.09]
  7 studies · 4420 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival: 5‐year survival rate (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 0.98 [0.86, 1.12]
  7 studies · 4389 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in adverse events: any (Duration of (low certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.12 [0.97, 1.28]
  4 studies · 4126 participants
  Low

Intervention not reported

The intervention showed no clear difference in adverse events: severe, grade > 2 (Duration of (low certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.14 [0.92, 1.4]
  6 studies · 4546 participants
  Low

Intervention not reported

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1081 participants
  Low

Intervention not reported

The intervention showed no clear difference in year overall survival in patients of poor performance status (WHO… (moderate certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.91, 1.02]
  7 studies · 911 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in oesophagitis (grade 3 to 4) (low certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 1.23 [0.81, 1.87]
  8 studies · 1301 participants
  Low

Intervention not reported

The intervention showed no clear difference in radiation Myelopathy (any grade) (moderate certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 1.29 [0.37, 4.51]
  11 studies · 2663 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in radiation pneumonitis (any grade) (low certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 0.62 [0.23, 1.66]
  3 studies · 533 participants
  Low